Adding ezetimibe to simvastatin improved cardiovascular outcomes in stable acute coronary syndrome.

Abstract

Patients: 18 144 adults ≥ 50 years of age (mean age 64 y, 76% men) who had been hospitalized in the past 10 days for an ACS and had LDL-C levels of 50 to 100 mg/dL (patients using lipidlowering therapy) or 50 to 125 mg/dL (patients not using longterm lipid-lowering therapy) ≤ 24 hours after ACS onset. Exclusion criteria included planned coronary artery bypass grafting, statin therapy with LDL-C–lowering potency equivalent to > 40 mg of simvastatin, creatinine clearance < 30 mL/min, or liver disease.

DOI: 10.7326/ACPJC-2015-163-6-007

Cite this paper

@article{Fordyce2015AddingET, title={Adding ezetimibe to simvastatin improved cardiovascular outcomes in stable acute coronary syndrome.}, author={Christopher B. Fordyce and Christopher B. Granger}, journal={Annals of internal medicine}, year={2015}, volume={163 6}, pages={JC7} }